{"id":303436,"date":"2026-10-13T09:24:21","date_gmt":"2026-10-13T03:54:21","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=303436"},"modified":"2026-10-13T09:24:21","modified_gmt":"2026-10-13T03:54:21","slug":"vaccine-formulation-and-pharmacy-chain-stocks-forward-growth-shortlist","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/vaccine-formulation-and-pharmacy-chain-stocks-forward-growth-shortlist\/","title":{"rendered":"3 Vaccine, Formulation and Pharmacy Chain Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, Lincoln Pharmaceuticals and Medplus Health Services"},"content":{"rendered":"

GSK Pharma Rs 2,531.50, P\/E 40.20. Lincoln Pharma Rs 543.50, P\/E 11.64. Medplus Rs 627.60, P\/E 36.06. Closing prices of 12 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Vaccine, formulation and pharmacy chain stocks with the clearest long-term roadmaps today include GSK Pharma in branded medicines and vaccines, Lincoln Pharma in formulations for India and export markets and Medplus in a pharmacy retail chain across several states. FY26 revenue growth was 1.8% at GSK Pharma, 9.1% at Lincoln Pharma and 12.6% at Medplus. P\/E stands at 40.20 for GSK Pharma (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Vaccine, formulation and pharmacy chain stocks give investors exposure to medicines, vaccines and pharmacy stores that patients use regularly. Prescription growth, store additions and margins decide how much of that demand turns into profit.<\/p>\n

This list covers three vaccine, formulation and pharmacy chain stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines, Lincoln Pharmaceuticals for formulations for India and export markets and Medplus Health Services for a pharmacy retail chain across several states. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n